Related news stories: More support from COSMIC-021 for cabozantinib–atezolizumab potential in advanced UC Cabozantinib–atezolizumab duo shows urothelial cancer potential in COSMIC-021 study TITAN-TCC: Ongoing Phase 2 Patient population: Patients with unresectable or metastatic transitional cell carcinoma who have progressed during or after first-line platinum-based chemotherapy and have received up to two further lines of treatment.

The 10-year data from the PRIME II trial suggest that radiotherapy after breast-conserving surgery can be omitted for women aged 65 years or older with low-risk, hormone receptor-positive early breast cancer.

These data “further support” the adjuvant use of abemaciclib in this patient population, he added.

End-of-study findings from the GIM2 trial indicate that adjuvant anthracyclines plus taxane chemotherapy for high-risk early breast cancer should be given in a dose-dense regimen and should not include fluorouracil.

Discordance between patient and clinician warrants follow-up or immediate referral to smoking cessation services.

“These findings support dalpiciclib plus letrozole or anastrozole as a new first-line treatment option,” he said.

Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature.

Writing in the Journal of Clinical Oncology , the study investigators conclude: “Our data support lorlatinib as first-line treatment in patients with advanced ALK -positive NSCLC with/without brain metastases.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group J Clin Oncol 2022; doi:10.1200/JCO.21.02278

And in light of the similar survival outcomes alongside the previously reported  significant improvements in endpoints such as prostate-specific antigen (PSA) response and progression-free survival (PFS), as well as the favorable safety profile and dosing schedule, “the TheraP data support the choice of [LuPSMA] over cabazitaxel for patients with PSMA-positive, progressive mCRPC after docetaxel and androgen receptor pathway inhibitors,” said Hofman.

The use of adjuvant chemotherapy in patients with hormone receptor-positive, HER2-negative early breast cancer and up to three positive lymph nodes could be guided by the 21-gene recurrence score and response to preoperative endocrine therapy, research suggests.

Extended follow-up data from the KEYNOTE-564 study show that adjuvant pembrolizumab continues to offer a disease-free survival benefit over placebo in people with renal cell carcinoma at an intermediate-high or high postsurgery recurrence risk.

“Our results support further investigation of CDK4 and CDK6 inhibition in the context of a molecularly stratified, randomised clinical trial” in this patient population, write the UK researchers in The Lancet Oncology .

When taken together with the current analysis of patient-reported outcomes (PROs), David Cella (Northwestern University, Chicago, Illinois, USA) and co-investigators say that the data “further support the use of nivolumab plus cabozantinib over sunitinib.”

Research from three countries adds support for the use of a booster dose of vaccines against SARS-CoV-2 in people with cancer, especially those undergoing active anticancer treatment.

However, when all healthcare and personal social services costs were taken into account the intervention was associated with an average cost saving of £ 387 ($ 516; € 457) per participant.

Real-world study data show that a high proportion of patients with metastatic clear cell renal cell carcinoma gain clinical benefit from treatment with cabozantinib following progression with immune checkpoint inhibitors.

Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature.

“These findings support the inclusion of carboplatin in neoadjuvant chemotherapy for stage II-III TNBC,” concluded Loibl. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group ESMO Congress 2021; 16–21 September

Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature.